- Home
- CNTA vs TWST Comparison
CNTA vs TWST Comparison
Compare CNTA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- TWST
- Stock Information
- Founded
- CNTA 2020
- TWST 2013
- Country
- CNTA United Kingdom
- TWST United States
- Employees
- CNTA N/A
- TWST N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTA Health Care
- TWST Health Care
- Exchange
- CNTA Nasdaq
- TWST Nasdaq
- Market Cap
- CNTA 2.3B
- TWST 2.7B
- IPO Year
- CNTA 2021
- TWST 2018
- Fundamental
- Price
- CNTA $16.46
- TWST $50.45
- Analyst Decision
- CNTA Strong Buy
- TWST Buy
- Analyst Count
- CNTA 8
- TWST 9
- Target Price
- CNTA $23.71
- TWST $52.33
- AVG Volume (30 Days)
- CNTA 470.8K
- TWST 708.5K
- Earning Date
- CNTA 11-12-2024
- TWST 02-04-2025
- Dividend Yield
- CNTA N/A
- TWST N/A
- EPS Growth
- CNTA N/A
- TWST N/A
- EPS
- CNTA N/A
- TWST N/A
- Revenue
- CNTA $6,853,000.00
- TWST $312,974,000.00
- Revenue This Year
- CNTA N/A
- TWST $21.67
- Revenue Next Year
- CNTA N/A
- TWST $17.52
- P/E Ratio
- CNTA N/A
- TWST N/A
- Revenue Growth
- CNTA N/A
- TWST 27.69
- 52 Week Low
- CNTA $7.38
- TWST $27.41
- 52 Week High
- CNTA $18.97
- TWST $60.90
- Technical
- Relative Strength Index (RSI)
- CNTA 50.86
- TWST 60.49
- Support Level
- CNTA $14.61
- TWST $44.35
- Resistance Level
- CNTA $17.65
- TWST $47.28
- Average True Range (ATR)
- CNTA 1.08
- TWST 2.74
- MACD
- CNTA -0.10
- TWST 0.27
- Stochastic Oscillator
- CNTA 56.74
- TWST 91.17
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.